London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today announces that it
has commenced the submission of a rolling Biologics
License Application (BLA) for Voraxaze with the Food and Drug
Administration (FDA) in the US. This marketing application is being
made for the interventional use of Voraxaze for the rapid and sustained
reduction of methotrexate (MTX) in patients who have toxic MTX levels
due to impaired renal function.
